VRTX241011C505000
- 0.41
- -2.24-84.53%
Vertex Pharmaceuticals Newsroom
Cantor Fitzgerald Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $480
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600
DBS Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Buy Rating Affirmed for Vertex Pharmaceuticals on Promising Pain Management Drug Prospects
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven by 'Strong AI Demand' And 'Margin Expansion'
Vortex Energy Brief: Says Completed Phase 1 Exploration at the Fire Eye Uranium Property, Saskatchewan and Amends Option Terms
Capricor Stock Rallies 20% on DMD Data Presentation Update
National Bank on DRI Healthcare's Casgevy Stream Acquisition
Vertex Pharmaceuticals Is Maintained at Sector Perform by RBC Capital
Express News | RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $425
Analysts Conflicted on These Healthcare Names: TransMedics Group (TMDX), Vertex Pharmaceuticals (VRTX) and Edwards Lifesciences (EW)
DBS Initiates Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Avidity Gets FDA Partial Clinical Hold Lifted on DM1 Drug Candidate
Reasons That Lifted Vertex Pharmaceuticals Incorporated (VRTX) in Q2
Bernstein Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating, Raises Target Price to $502
Wolfe Research Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Announces Target Price $518
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $518 From $576, Maintains Outperform Rating
What Analysts Are Saying About Vertex Pharmaceuticals Stock
Vertex Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley